MEXICO CITY , Nov. 5, 2025 /PRNewswire/ -- Grupo Aeroportuario del Sureste, S.A.B. de C.V. (NYSE: ASR; BMV: ASUR), ASUR, a leading international airport group with operations in Mexico, the U.S. and Colombia, at the request of the Mexican Stock Exchange ("BMV") and in compliance with article 50 of the provisions applicable to securities issuers ("Circular Única de Emisoras"), confirms that it has submitted an offer to Motiva Infraestructura de Mobilidade S.A.

The Trump administration has limited options to refill the Strategic Petroleum Reserves.

Zimmer Biomet, the maker of knee and hip replacements, missed on quarterly sales estimates and lowered the top end of its outlook for full-year organic revenue growth.

As of Oct. 31, SA Quant's Top 10 Stocks for 2025 have significantly outperformed the S&P 500, gaining nearly 45% vs. the S&P 500's 18%. Two out of 10 stocks have delivered triple-digit returns, with Celestica delivering an incredible 236% since it was selected on Jan. 9, 2025. While only three stocks are Quant-rated ‘Buy' or ‘Strong Buys,' the list remains fundamentally strong, with several stocks primed for long-term outperformance.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming December 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Synopsys, Inc. (“Synopsys” or the “Company”) (NASDAQ: SNPS) securities between December 4, 2024 and September 9, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR SYNOPSYS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired CarMax, Inc. (“CarMax” or the “Company”) (NYSE: KMX) securities between June 20, 2025 and September 24, 2025, inclusive (the “Class Period”). CarMax investors have until January 2, 2026 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR CARMAX, I.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming December 23, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased James Hardie Industries plc (“James Hardie” or the “Company”) (NYSE: JHX) common stock (previously American Depositary Shares until the Company's conversion to common stock on July 1, 2025) between May 20, 2025 and August 18, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR W.

CHARLOTTE, N.C.--(BUSINESS WIRE)--The American Gambling Awards is pleased to announce that Chairman Christopher Hebert has been named Regulator of the Year for 2025. The American Gambling Awards, produced by Gambling.com Group Limited (Nasdaq: GAMB) ("Gambling.com Group" or the "Group"), honor the top companies and executives shaping the regulated U.S. online gambling landscape and are recognized as a benchmark for excellence in the sector. “I am honored to receive this recognition from the Ame.

HOUSTON--(BUSINESS WIRE)--RCI Hospitality Holdings, Inc. (Nasdaq: RICK) today issued an update on previously-announced plans to sell assets in line with the Company's “Back to Basics” 5-Year Capital Allocation Plan. RCI announced closing on the sale of a small club business in Harlingen, TX for $600,000 cash and a $180,000 annual lease, which starts January 1, 2026. The transaction closed today. The Company said three non-income producing properties have letters of intent or are under contract.

Syndax Pharmaceuticals, Inc. remains a Buy, with Revuforj and Niktimvo launches accelerating and a strong clinical and commercial trajectory into 2026. Revuforj's recent NPM1 AML approval expands its addressable market, reinforcing first-mover advantage and supporting $1B+ peak sales potential. Niktimvo's robust uptake and Incyte partnership will aid the march to profitability, while also providing significant downside cushion.

Kinross Gold Corporation (TSX:K) (NYSE: KGC) late Tuesday reported third quarter 2025 adjusted earnings per share of $0.44, surpassing the analyst consensus estimate of $0.39. The company's revenue for the quarter rose 25.8% year over year to $1.8 billion on a stronger gold price.

Bio-Techne's Q1 earnings meet expectations, but revenues slip 1%, sending shares lower despite stronger margins.

SMP's Q3 earnings and revenues beat estimates as strong Temperature Control sales lift results and full-year guidance improves.

Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.

SRE beats on Q3 earnings with a 24.7% rise in adjusted EPS, reaffirming its full-year outlook.

FLO's third-quarter results are likely to show revenue growth from branded retail strength, though earnings may fall on softer volumes.

Fresenius Medical Care's Q3 earnings and revenues beat estimates, fueled by margin gains and solid organic growth across segments.

AMD's Q3 beat & AI supercomputer deals signal strong growth, but Amazon's exit makes investment in diversified ETFs like SOXX and IGPT a smart move.

CQP Q3 earnings fall short of estimates as higher operating costs weigh on results despite revenue gains.

Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.05 per share a year ago.